This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Nair, S. Articles by Gilboa, E. Search for Related Content PubMed PubMed Citation Articles by Nair, S. Articles by Gilboa, E.

Vaccination against the Forkhead Family Transcription Factor Foxp3 Enhances Tumor Immunity

Departments of ¹ Surgery, Duke Center for Translational Research and ² Medicine, Duke University Medical Center, Durham, North Carolina and ³ Department of Internal Medicine I, University of Wuerzburg, Wuerzburg, Germany

Requests for reprints: Eli Gilboa, Miller School of Medicine, University of Miami, P.O. Box 019132 (M877), Miami, FL 33101. Phone: 305-243-1767; Fax: 305-243-4409; E-mail: egilboa{at}med.miami.edu.

Depletion of CD4⁺CD25⁺ regulatory T cells (Treg) by treatment with CD25 antibody synergizes with vaccination protocols to engender protective immunity in mice. The effectiveness of targeting CD25 to eliminate Treg is limited by the fact that CD25, the low-affinity interleukin-2 receptor, is up-regulated on conventional T cells. At present, foxp3 is the only product known to be exclusively expressed in Treg of mice. However, foxp3 is not expressed on the cell surface and hence cannot be targeted with antibodies. In this study, we tested the hypothesis that vaccination of mice against foxp3, a self-antigen expressed also in the thymus, is capable of stimulating foxp3-specific CTL that will cause the depletion of Treg and enhanced antitumor immunity. Vaccination of mice with foxp3 mRNA-transfected dendritic cells elicited a robust foxp3-specific CTL response and potentiated vaccine-induced protective immunity comparably with that of CD25 antibody administration. In contrast to CD25 antibody treatment, repeated foxp3 vaccination did not interfere with vaccine-induced protective immunity. Importantly, foxp3 vaccination led to the preferential depletion of foxp3-expressing Treg in the tumor but not in the periphery, whereas CD25 antibody treatment led to depletion of Treg in both the tumor and the periphery. Targeting foxp3 by vaccination offers a specific and simpler protocol for the prolonged control of Treg that may be associated with reduced risk of autoimmunity, introducing an approach whereby specific depletion of cells is not limited to targeting products expressed on the cell surface. [Cancer Res 2006;67(1):371–80]

This article has been cited by other articles:

				L. M. Ebert, B. S. Tan, J. Browning, S. Svobodova, S. E. Russell, N. Kirkpatrick, C. Gedye, D. Moss, S. P. Ng, D. MacGregor, et al. The Regulatory T Cell-Associated Transcription Factor FoxP3 Is Expressed by Tumor Cells Cancer Res., April 15, 2008; 68(8): 3001 - 3009. [Abstract] [Full Text] [PDF]

				T. H. Schreiber The Use of FoxP3 as a Biomarker and Prognostic Factor for Malignant Human Tumors Cancer Epidemiol. Biomarkers Prev., October 1, 2007; 16(10): 1931 - 1934. [Abstract] [Full Text] [PDF]

				P. Hubert, N. Jacobs, J.-H. Caberg, J. Boniver, and P. Delvenne The cross-talk between dendritic and regulatory T cells: good or evil? J. Leukoc. Biol., October 1, 2007; 82(4): 781 - 794. [Abstract] [Full Text] [PDF]

				D. J. Powell Jr., A. Felipe-Silva, M. J. Merino, M. Ahmadzadeh, T. Allen, C. Levy, D. E. White, S. Mavroukakis, R. J. Kreitman, S. A. Rosenberg, et al. Administration of a CD25-Directed Immunotoxin, LMB-2, to Patients with Metastatic Melanoma Induces a Selective Partial Reduction in Regulatory T Cells In Vivo J. Immunol., October 1, 2007; 179(7): 4919 - 4928. [Abstract] [Full Text] [PDF]